1998
DOI: 10.1590/s0102-311x1998000400014
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: The safety profile of a drug is not a static concept. It progresses and can change on the basis of scientific data gathered before and after it is marketed. Therefore, it is now considered

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
3
0
1

Year Published

2000
2000
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 6 publications
0
3
0
1
Order By: Relevance
“…9 However, this problem does not seem to affect exclusively Brazil. Researchers from the United Kingdom 10 and Portugal 11 have shown that the amount of time dedicated to teaching pharmacovigilance in undergraduate and graduate pharmacy and medical courses is low. These results reinforce the need of greater attention at university education level to the subjects of Pharmacovigilance.…”
Section: Discussionmentioning
confidence: 99%
“…9 However, this problem does not seem to affect exclusively Brazil. Researchers from the United Kingdom 10 and Portugal 11 have shown that the amount of time dedicated to teaching pharmacovigilance in undergraduate and graduate pharmacy and medical courses is low. These results reinforce the need of greater attention at university education level to the subjects of Pharmacovigilance.…”
Section: Discussionmentioning
confidence: 99%
“…(32) The National Pharmacovigilance System (SNF) was created centrally in 1992 a , and has an essential role in the ongoing evaluation of the benefit/risk balance of medicines. (33) The national pharmacovigilance system is a key tool for monitoring and ensuring the safety of patients, with a view to the protection of public health.…”
Section: Pharmacovigilance In Portugalmentioning
confidence: 99%
“…Por este motivo, os países capazes de monitorar de forma contínua a segurança dos medicamentos que comercializam devem fazê-lo, e, na ausência dessa capacitação, que priorizem, dentro das políticas implementadas, o desenvolvimento de instrumentos para este fim. A identificação das reações adversas deve estar vinculada à criação de normas, pelo Estado, a fim de garantir a qualidade de medicamentos e proteger a saúde da população (Corrêa Nunes, 1998). Uma cultura em que se valoriza a vigilância sobre os efeitos adversos dos medicamentos tem como conseqüências a fiscalização de todo o processo produtivo, bem como a detecção de falhas na qualidade e de fraudes.…”
Section: Farmacovigilânciaunclassified